$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Hematology
Hematology
恩西地平可以用于治疗急性髓系白血病吗?
2025-10-19 11:44:20
Check Details
奈拉滨的出现使白血病患者有了希望!
2025-10-19 11:44:20
Check Details
依维替尼治疗急性骨髓性白血病的安全性和有效性
2025-10-19 11:44:20
Check Details
急性髓性白血病患者服用恩西地平治疗的效果
2025-10-19 11:44:20
Check Details
白血病新药艾伏尼布使用禁忌和用药注意事项
2025-10-19 11:44:20
Check Details
白血病患者使用恩西地平需要了解的事项
2025-10-19 11:44:20
Check Details
吉瑞替尼用于治疗复发或难治性急性髓系白血病(AML)合并FLT3的成人患者
2025-10-19 11:44:20
Check Details
急性髓系白血病新药吉瑞替尼在中国获批上市了吗?
2025-10-19 11:44:20
Check Details
白血病新药吉瑞替尼可显著改善患者生存期
2025-10-19 11:44:20
Check Details
首个肿瘤代谢药恩西地平在中国获批上市了吗?
2025-10-19 11:44:20
Check Details
治疗急性髓系白血病(AML)的突破性疗法-吉瑞替尼
2025-10-19 11:44:20
Check Details
吉瑞替尼治疗FJT3急性髓系白血病的生存期
2025-10-19 11:44:20
Check Details
1
2
...
603
604
605
606
607
608
609
...
938
939
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
In-Depth Analysis of Selinexor (Xpovio): A Novel Nuclear Export Blockade Option for Relapsed/Refractory Multiple Myeloma and Latest Clinical Advances
2
Acalabrutinib BTK Covalent Inhibition: CLL/SLL Signaling Blockade, Non-Selective Effects, and Progression Monitoring
3
Bosutinib for Ph+ CML: Eligible Populations, Food-Dependent Dosing, Diarrhea and Hepatotoxicity Monitoring
4
Venetoclax BCL-2 Inhibitor: CLL/SLL and AML Ramp-Up, Tumor Lysis Prevention, and Selected Overseas Combination Updates
5
First-Line Pirtobrutinib Without 17p Deletion in CLL/SLL: Noncovalent BTK vs BR, Median PFS Not Reached, HR 0.20
6
Belumosudil for cGVHD: 200mg with Food, Pregnancy Contraception, Liver Monitoring, Drug Interactions
7
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
8
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
9
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
AZA+VEN+IVO Triplet Therapy for Newly Diagnosed IDH1 AML: High Response Rates and Durable Efficacy
12
Anagrelide and Myelofibrosis Risk: Controversy and Monitoring in ET Treatment